MedPharm || طبصيدلة

patient with chronic insomnia was treated by zolpidem and educated about sleep hygiene. Which one of the following statements regarding the evaluation of therapeutic outcome for this patient is true? a- After 1 week of therapy, the patient should be assessed for drug adherence, effectiveness, and adverse events b- After 7 days of therapy, the patient should be assessed for drug effectiveness, adverse events, and adherence to non-pharmacologic recommendations c- After 1 week of therapy, the patient should be assessed for drug effectiveness, and adverse events d- After 1 month of therapy, the patient should be assessed for drug effectiveness, adverse events, and adherence to non-pharmacologic recommendations e- None of the above

M.K. is 47 years-old man who requested a treatment that can help him fall asleep rapidly and does not affect his ability to drive his taxi in the early morning. He has concerns about rebound insomnia. Which one of the following drugs is the best for treating the patient case?

Obstructive sleep apnea (OSA) is potentially life-threatening and characterized by repeated episodes of nocturnal breathing cessation followed by blood oxygen desaturation. Which one of the following drugs is approved by the FDA to improve wakefulness in those with residual daytime sleepiness?

Saleema, a 53-years-old schoolteacher complains of inability to sleep well for more than two years. She regularly goes to bed at 10 pm but is unable to sleep until 1 am. She experiences about 3-5 awakenings every night and with each awakening requires about 30 minutes to fall asleep again. Saleema also experiences daytime fatigue and is unable to concentrate on her work. She does not snore during sleep. Her general health has been good except for a history of well-controlled open-angle glaucoma. What is the management of choice that can be offered for this patient?